Critical Design Strategies Supporting Optimized Drug Release from Polymer-Drug Conjugates.

Autores de CIPF
Grupos de Investigación
Abstract
The importance of an adequate linking moiety design that allows controlled drug(s) release at the desired site of action is extensively studied for polymer-drug conjugates (PDCs). Redox-responsive self-immolative linkers bearing disulfide moieties (SS-SIL) represent a powerful strategy for intracellular drug delivery; however, the influence of drug structural features and linker-associated spacers on release kinetics remains relatively unexplored. The influence of drug/spacer chemical structure and the chemical group available for conjugation on drug release and the biological effect of resultant PDCs is evaluated. A "design of experiments" tool is implemented to develop a liquid chromatography-mass spectrometry method to perform the comprehensive characterization required for this systematic study. The obtained fit-for-purpose analytical protocol enables the quantification of low drug concentrations in drug release studies and the elucidation of metabolite presence. and provides the first data that clarifies how drug structural features influence the drug release from SS-SIL and demonstrates the non-universal nature of the SS-SIL. The importance of rigorous linker characterization in understanding structure-function correlations between linkers, drug chemical functionalities, and in vitro release kinetics from a rationally-designed polymer-drug nanoconjugate, a critical strategic crafting methodology that should remain under consideration when using a reductive environment as an endogenous drug release trigger.
Datos de la publicación
- ISSN/ISSNe:
- 1613-6810, 1613-6829
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 37752780
Small WILEY-V C H VERLAG GMBH
Citas Recibidas en Web of Science: 7
Documentos
- No hay documentos
Filiaciones
Keywords
- design of experiment, drug delivery, drug release kinetics, polymer-drug conjugates, redox-responsive self-immolative linkers, structure-activity relationship
Proyectos asociados
SENSITIZING PANCREATIC CANCER TO IMMUNOTHERAPY WITH MULTIMODAL PRECISION NANOMEDICINES
Investigador Principal: MARIA JESUS VICENT DOCON
FUNDACIÓN LA CAIXA . 2019
Molecular Machines Functioning in Cells
Investigador Principal: MARIA JESUS VICENT DOCON
COMMISSION OF EUROPEAN COMMUNITIES . 2020
Aproximación sinérgica al desarrollo de terapias para tumores metastásicos y desórdenes neurodegenarativos utilizando conjugados polipetídicos versátiles
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2020
Versatile Polypeptide-based Intranasal Drug Delivery Platform(s) to Tackle CNS Disorders. ERC. POLYBRAINT
Investigador Principal: MARIA JESUS VICENT DOCON
COMMISSION OF EUROPEAN COMMUNITIES . 2022
Incorporacion nuevos grupos al CIBER CIBERONC. Punto 3.2 Immunoterapia para tumores sólidos. NOTA: el presupuesto concedido es para le CIBER no para el CIPF
Investigador Principal: MARIA JESUS VICENT DOCON
2022
Nanoplataforma Polipeptídica Multimodal de Precisión para el Tratamiento y Monitorización de Tumores Metastásicos. Colab I-36, I-12, I-63, servicio citómica, uji y gva (Esther Roselló)
Investigador Principal: MARIA JESUS VICENT DOCON
CONSELLERIA DE EDUCACION . 2022
New nanotechnological therapy for Parkinson´s disease: nose to brain delivery of GBA-polymer nanoconjugates
Investigador Principal: MARIA JESUS VICENT DOCON
FUNDACIÓN LA CAIXA . 2022
VI RSEQ Chemical Biology Group Meeting- ChemBioVI
Investigador Principal: MARIA JESUS VICENT DOCON
2023
MULTISMART, Multi-component Soft Materials Advanced Research Training Network
Investigador Principal: MARIA JESUS VICENT DOCON
COMMISSION OF EUROPEAN COMMUNITIES . 2023
Providing cutting edge cancer research services across Europe (CanSERV)
Investigador Principal: MARIA JESUS VICENT DOCON
COMMISSION OF EUROPEAN COMMUNITIES . 2022
Sinergias en descubrimiento de fármacos en España. ES-OPENSCREEN_2
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2023